It’s a tie: Sanofi and Novo come in neck-and-neck at the FDA with two new diabetes combo OKs
Sanofi and Novo Nordisk tried mightily to beat each other to the finish line first with a combination of their long-lasting insulin with their GLP1 drugs. But the FDA decided to call it a draw.
Regulators in the US simultaneously approved Novo’s Xultophy — a combination of Tresiba and Victoza on the market in Europe for the past two years — and Sanofi’s Soliqua, which combines Lantus and Lyxumia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.